DoorDash, Inc. Class A Common Stock (DASH)vsWest Pharmaceutical Services Inc (WST)
DASH
DoorDash, Inc. Class A Common Stock
$152.92
-1.17%
CONSUMER CYCLICAL · Cap: $67.22B
WST
West Pharmaceutical Services Inc
$247.02
+0.71%
HEALTHCARE · Cap: $17.68B
Smart Verdict
WallStSmart Research — data-driven comparison
DoorDash, Inc. Class A Common Stock generates 346% more annual revenue ($13.72B vs $3.07B). WST leads profitability with a 16.1% profit margin vs 6.8%. DASH appears more attractively valued with a PEG of 1.58. DASH earns a higher WallStSmart Score of 59/100 (C).
DASH
Buy59
out of 100
Grade: C
WST
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-75.2%
Fair Value
$100.15
Current Price
$152.92
$52.77 premium
Margin of Safety
-256.8%
Fair Value
$68.99
Current Price
$247.02
$178.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37.7% year-over-year
Large-cap with strong market position
Earnings expanding 47.7% YoY
Safe zone — low bankruptcy risk
Strong operational efficiency at 21.6%
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
6.8% margin — thin
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
2.1% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : DASH
The strongest argument for DASH centers on Revenue Growth, Market Cap, EPS Growth. Revenue growth of 37.7% demonstrates continued momentum.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.
Bear Case : DASH
The primary concerns for DASH are PEG Ratio, Altman Z-Score, Profit Margin. A P/E of 72.3x leaves little room for execution misses.
Bear Case : WST
The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
DASH profiles as a hypergrowth stock while WST is a mature play — different risk/reward profiles.
DASH carries more volatility with a beta of 1.90 — expect wider price swings.
DASH is growing revenue faster at 37.7% — sustainability is the question.
DASH generates stronger free cash flow (254M), providing more financial flexibility.
Bottom Line
DASH scores higher overall (59/100 vs 55/100) and 37.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DoorDash, Inc. Class A Common Stock
CONSUMER CYCLICAL · INTERNET RETAIL · USA
DoorDash, Inc. operates a logistics platform that connects merchants, consumers, and merchants in the United States and internationally. The company is headquartered in San Francisco, California.
Visit Website →West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other INTERNET RETAIL Stocks
Want to dig deeper into these stocks?